Common Contracts
31 similar Placement Agency Agreement contracts by Qualigen Therapeutics, Inc., Athersys, Inc / New, Foresight Autonomous Holdings Ltd., others
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • September 30th, 2024 • Theriva Biologics, Inc. • Pharmaceutical preparations • New York
ContractPlacement Agency Agreement • September 16th, 2024 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”) and INmune Bio Inc., a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”) and (ii) warrants to purchase Common Stock (the “Common Warrants”). The Common Stock and Common Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with the Placement, including, without limitation, a securities purchase agreement (the “Purchase Agreement”), shall be collectively referred to herein as the “Tra
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • September 10th, 2024 • Theriva Biologics, Inc. • Pharmaceutical preparations • New York
Placement Agency AgreementPlacement Agency Agreement • September 9th, 2024 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • New York
Placement Agency AgreementPlacement Agency Agreement • August 22nd, 2024 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • New York
ContractPlacement Agency Agreement • June 13th, 2024 • Cibus, Inc. • Agricultural chemicals • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”) and Cibus, Inc., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of securities of the Company, consisting of: (i) shares of Class A common stock, par value $0.0001 per share (“Common Stock”) and (ii) warrants to purchase Common Stock (the “Common Warrants”). The Common Stock and Common Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with the Placement, including, without limitation, a securities purchase agreement (the “Purchase Agreement”), shall be collectively referred to herein as t
ContractPlacement Agency Agreement • April 11th, 2024 • Velo3D, Inc. • Special industry machinery, nec • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”), as sole placement agent, and Velo3D, Inc., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities of the Company, consisting of: (i) shares of common stock, par value $0.00001 per share (“Common Stock”), and (ii) warrants to purchase Common Stock (the “Common Warrants”). The Common Stock and Common Warrants actually sold by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities and shares of Common Stock issuable upon the exercise of the Warrants shall be offered and sold under the Company’s registration statement on Form S-3 (File No. 333-268346) (the “Registration Statement”), whic
ContractPlacement Agency Agreement • April 5th, 2024 • Matinas BioPharma Holdings, Inc. • Pharmaceutical preparations • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”) and Matinas BioPharma Holdings, Inc., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.0001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with th
TONIX PHARMACEUTICALS HOLDING CORP. 8-KPlacement Agency Agreement • March 29th, 2024 • Tonix Pharmaceuticals Holding Corp. • Pharmaceutical preparations • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”), as sole placement agent, and Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, in connection with the proposed registered direct offering (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) Series E warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually sold by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities and shares of Common Stock issuable upon the exercise of the Warrants shall be
ContractPlacement Agency Agreement • March 15th, 2024 • SELLAS Life Sciences Group, Inc. • Pharmaceutical preparations • New York
SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, NY 10036 Attention: Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer
ContractPlacement Agency Agreement • January 30th, 2024 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (the “Common Stock”); (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”) and (ii) warrants to purchase Common Stock (the “Common Warrants” and together with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Shares, Pre-Funded Warrants and shares o
ContractPlacement Agency Agreement • January 8th, 2024 • SELLAS Life Sciences Group, Inc. • Pharmaceutical preparations • New York
SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, NY 10036 Attention: Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer
TONIX PHARMACEUTICALS HOLDING CORP. 8-KPlacement Agency Agreement • December 21st, 2023 • Tonix Pharmaceuticals Holding Corp. • Pharmaceutical preparations • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”), as sole placement agent, and Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, in connection with the proposed registered direct offering (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) Series C warrants and Series D warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually sold by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities and shares of Common Stock issuable upon the exercise of
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 11th, 2023 • Motus GI Holdings, Inc. • Surgical & medical instruments & apparatus • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 8th, 2023 • Foresight Autonomous Holdings Ltd. • Services-prepackaged software • New York
ContractPlacement Agency Agreement • December 6th, 2023 • Meta Materials Inc. • Semiconductors & related devices • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Meta Materials Inc., a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”); and (ii) Warrants to purchase Common Stock (the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities and shares of Common Stock issuable upon the exercise of the Warrants shall be offered and sold under the Company’s registration statement on Form S-3 (File No. 333-2
ContractPlacement Agency Agreement • November 1st, 2023 • Zivo Bioscience, Inc. • Biological products, (no disgnostic substances) • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Zivo Bioscience, Inc., a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities and shares of C
ContractPlacement Agency Agreement • October 24th, 2023 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Kintara Therapeutics, Inc., a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities and shares
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • August 18th, 2023 • Athersys, Inc / New • Pharmaceutical preparations • New York
ContractPlacement Agency Agreement • August 15th, 2023 • 180 Life Sciences Corp. • Pharmaceutical preparations • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and 180 Life Sciences Corp., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities of the Company, consisting of: (i) shares of common stock, par value $0.0001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities and shares
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • August 7th, 2023 • Athersys, Inc / New • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • July 26th, 2023 • Athersys, Inc / New • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 1st, 2021 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • February 3rd, 2021 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (“A.G.P.”)(A.G.P. is also referred to as, the “Placement Agent”), and Pluristem Therapeutics Inc., a company organized under the laws of the State of Nevada (the “Company”), that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of shares of common stock, par value, $0.00001 per share (the “Shares”). The Shares actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities shall be offered and sold under the Company’s registration statement on Form S-3 (File No. 333-239890) with respect to the Placement Agent Securities. The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with the Placement, including, without limitation, a securities pu
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • January 12th, 2021 • PECK Co HOLDINGS, INC. • Semiconductors & related devices • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 18th, 2020 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • September 10th, 2020 • Village Farms International, Inc. • Agricultural production-crops • New York
This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Village Farms International, Inc., a Canadian corporation (the “Company”), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of (i) shares (the “Shares”) of the Company’s Common Shares, no par value (the “Common Shares”) and (ii) warrants, each to purchase one-half (0.5) Common Shares (the “Warrants” and together with the Shares, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.”). The terms of the Placement shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”), and nothing herein constitutes that the Placement Agent would have the power or authority to bind the Company or any Purchase
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • August 28th, 2020 • Motus GI Holdings, Inc. • Surgical & medical instruments & apparatus • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • August 4th, 2020 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • July 9th, 2020 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • June 11th, 2020 • Foresight Autonomous Holdings Ltd. • Services-prepackaged software • New York
